Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
(→ATC: err) |
No edit summary |
||
| Line 20: | Line 20: | ||
<ref>http://www.whocc.no/atc_ddd_index/?code=C10AB02</ref></center> | <ref>http://www.whocc.no/atc_ddd_index/?code=C10AB02</ref></center> | ||
|} | |} | ||
<references/> | <references/> | ||
https://www.wikidata.org/wiki/Q577387 | |||
[[Category:Hepatotoxic substances]] | [[Category:Hepatotoxic substances]] | ||
Revision as of 18:32, 6 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases This fibrate reduce triglyceride and riseHDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
- ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02